Vectormune ND
Newcastle disease and Marek’s disease vaccine (live recombinant)
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Vectormune ND. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Vectormune ND.
For practical information about using Vectormune ND, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Vectormune ND
|
Agency product number |
EMEA/V/C/003829
|
Active substance |
cell-associated live recombinant turkey herpes virus (rHVT/ND) expressing the fusion protein of Newcastle diseases virus D-26 lentogenic strain
|
International non-proprietary name (INN) or common name |
Newcastle disease and Marek’s disease vaccine (live recombinant)
|
Species |
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI01AD
|
Publication details | |
---|---|
Marketing-authorisation holder |
CEVA-Phylaxia Co. Ltd.
|
Revision |
6
|
Date of issue of marketing authorisation valid throughout the European Union |
08/09/2015
|
Contact address |
Product information
20/07/2020 Vectormune ND - EMEA/V/C/003829 - R/0013
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
-
Immunologicals for aves
-
Live viral vaccines
Therapeutic indication
For active immunisation of 18 day-old embryonated chicken eggs or one-day-old chicks to reduce mortality and clinical signs caused by Newcastle disease virus and to reduce mortality, clinical signs and lesions caused by Marek’s disease virus with a phenotype "virulent".